Stimulation of Ovulation in Immature Female Rats Using Orthosteric and Allosteric Luteinizing Hormone Receptor...

Area of Science:

• Reproductive Endocrinology
• Pharmacology

Background:

• Human chorionic gonadotropin (hCG) and luteinizing hormone (LH) are standard treatments for reproductive disorders and ovulation induction.
• Their clinical use is restricted by potential side effects.

Purpose of the Study:

• To evaluate TP03, an allosteric agonist of the LH/hCG receptor, as a potential alternative to hCG and LH.
• To assess TP03's efficacy in inducing ovulation and stimulating ovarian steroidogenesis.

Main Methods:

• Immature female rats were pretreated with Follimag.
• TP03 (50 mg/rat, i.p.) was administered.
• Progesterone levels and corpus luteum formation were assessed post-treatment.
• Vascular endothelial growth factor (VEGF) expression was analyzed.

Main Results:

• TP03 administration increased progesterone levels within 8 hours and induced ovulation, evidenced by corpus luteum formation (8.6 ± 0.5 per ovary at 24 h).
• TP03 demonstrated comparable activity to hCG but with a more moderate effect.
• Unlike hCG, TP03 did not elevate VEGF expression, mitigating the risk of ovarian hyperstimulation syndrome.

Conclusions:

• TP03 is a potent ovulation inducer and ovarian steroidogenesis stimulator.
• Its mechanism of action offers a potentially safer alternative to hCG, avoiding VEGF-related side effects.
• TP03 represents a promising therapeutic candidate for reproductive treatments.